AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$UTHR

ROTHBLATT MARTINE A sold $5.1M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $538.67 ($527.90–$545.50, $5.12M total) across 17 trades on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Oct 7, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
high confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a bearish cue, though the pre‑arranged nature tempers the signal.

02

Market read

The filing is a primary source of new information about insider activity, offering a modest trading cue for UTHR.

03

What to watch

The 10b5‑1 plan may have been set months ago, and the sale size is modest relative to market cap.

Relevance 5/10Novelty 7/10Timing: today

Background

Form 4 filings provide the first public disclosure of insider transactions, which traders monitor for potential signals.

Company-level read

Ticker impact

$UTHRBearishHigh confidence
Context

CEO Martine A. Rothblatt sold $5.1M of UTHR shares via a 10b5‑1 plan, reducing her stake to 324,443 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $5M open‑market sale by the chairperson and CEO is material and disclosed for the first time, prompting traders to watch for sell‑off.

Market effects

Sector

Minimal impact on the biotech sector; the sale is company‑specific.

Regional

U.S. market only; no broader regional effect.

Global

Limited to investors tracking United Therapeutics.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move under a pre‑arranged plan, not a negative signal.

Key entities

  • person
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics

  • company
    United Therapeutics Corp

    Biopharmaceutical company listed on NASDAQ under ticker UTHR

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min